🚀 VC round data is live in beta, check it out!
Herantis Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Herantis Pharma and similar public comparables like Dogwood Therapeutics, Corestemchemon, THX Pharma, Actuate Therapeutics and more.
Herantis Pharma Overview
About Herantis Pharma
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson’s disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
Founded
2014
HQ
Employees
11
Website
Sectors
Financials (LTM)
EV
$53M
Herantis Pharma Financials
Herantis Pharma reported last 12-month revenue of $12K and negative EBITDA of ($7M).
In the same LTM period, Herantis Pharma generated ($7M) in EBITDA losses.
Revenue (LTM)
Herantis Pharma P&L
In the most recent fiscal year, Herantis Pharma reported revenue of $12K and EBITDA of ($7M).
Herantis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $12K | XXX | $12K | XXX | XXX | XXX |
| EBITDA | ($7M) | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | (57843%) | XXX | (63990%) | XXX | XXX | XXX |
| EBIT Margin | (57842%) | XXX | (63990%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (67349%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Herantis Pharma Stock Performance
Herantis Pharma has current market cap of $56M, and enterprise value of $53M.
Market Cap Evolution
Herantis Pharma's stock price is $2.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53M | $56M | 0.6% | XXX | XXX | XXX | $-0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHerantis Pharma Valuation Multiples
Herantis Pharma trades at 4546.6x EV/Revenue multiple, and (7.9x) EV/EBITDA.
EV / Revenue (LTM)
Herantis Pharma Financial Valuation Multiples
As of April 18, 2026, Herantis Pharma has market cap of $56M and EV of $53M.
Equity research analysts estimate Herantis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Herantis Pharma has a P/E ratio of (7.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $56M | XXX | $56M | XXX | XXX | XXX |
| EV (current) | $53M | XXX | $53M | XXX | XXX | XXX |
| EV/Revenue | 4546.6x | XXX | 4573.6x | XXX | XXX | XXX |
| EV/EBITDA | (7.9x) | XXX | (7.1x) | XXX | XXX | XXX |
| EV/EBIT | (7.9x) | XXX | (7.1x) | XXX | XXX | XXX |
| P/E | — | XXX | (7.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Herantis Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Herantis Pharma Margins & Growth Rates
Herantis Pharma's revenue in the last 12 month grew by 1%.
Herantis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Herantis Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | (57843%) | XXX | (63990%) | XXX | XXX | XXX |
| EBITDA Growth | (8%) | XXX | (31%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 65065% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Herantis Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Herantis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogwood Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corestemchemon | XXX | XXX | XXX | XXX | XXX | XXX |
| THX Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kezar Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Herantis Pharma M&A Activity
Herantis Pharma acquired XXX companies to date.
Last acquisition by Herantis Pharma was on XXXXXXXX, XXXXX. Herantis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Herantis Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHerantis Pharma Investment Activity
Herantis Pharma invested in XXX companies to date.
Herantis Pharma made its latest investment on XXXXXXXX, XXXXX. Herantis Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Herantis Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Herantis Pharma
| When was Herantis Pharma founded? | Herantis Pharma was founded in 2014. |
| Where is Herantis Pharma headquartered? | Herantis Pharma is headquartered in Finland. |
| How many employees does Herantis Pharma have? | As of today, Herantis Pharma has over 11 employees. |
| Is Herantis Pharma publicly listed? | Yes, Herantis Pharma is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Herantis Pharma? | Herantis Pharma trades under HRTIS ticker. |
| When did Herantis Pharma go public? | Herantis Pharma went public in 2014. |
| Who are competitors of Herantis Pharma? | Herantis Pharma main competitors are Dogwood Therapeutics, Corestemchemon, THX Pharma, Actuate Therapeutics. |
| What is the current market cap of Herantis Pharma? | Herantis Pharma's current market cap is $56M. |
| What is the current revenue of Herantis Pharma? | Herantis Pharma's last 12 months revenue is $12K. |
| What is the current revenue growth of Herantis Pharma? | Herantis Pharma revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Herantis Pharma? | Current revenue multiple of Herantis Pharma is 4546.6x. |
| Is Herantis Pharma profitable? | No, Herantis Pharma is not profitable. |
| What is the current EBITDA of Herantis Pharma? | Herantis Pharma has negative EBITDA and is not profitable. |
| What is Herantis Pharma's EBITDA margin? | Herantis Pharma's last 12 months EBITDA margin is (57843%). |
| What is the current EV/EBITDA multiple of Herantis Pharma? | Current EBITDA multiple of Herantis Pharma is (7.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.